Clinical Trial

Impact of a Community Based Engagement Program Focused on Adolescents With Epilepsy

Study acronym: AWE-Change
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2023 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this community based observation study is to co-create solutions that empower people to make informed decisions about epilepsy, reduce stigma, and promote community health among the adolescent population living with epilepsy in Uganda. The main objectives of the study are to: Goal 1: Co-create a unique patient-community engagement program (CEP) to reduce stigma on epilepsy among adolescents and their caregivers in Uganda based on understanding of the illness. Goal 2: Evaluate the impact of this CEP to reduce stigma on epilepsy among adolescents and their caregivers in Uganda, based on understanding of the illness. Study participants together with the relevant community stakeholders will co-design feasible communication and activity-based change projects that are based on both cultural and scientific norms, to reduce epilepsy stigma in the community Researchers will then compare the Quality of Life, Attitudes and Beliefs about Living with Epilepsy scores (as a surrogate of stigmatizing beliefs and practices among community members) and the Kilifi Stigma Scale scores in two parishes (urban and rural) to see if there is improvement in these assessments scores following the implementation of the community change projects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-20; most recent amendment 2023-08-30.
Trial Details
NCT Number NCT05660239
Lead Sponsor Makerere University
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Duke University
Conditions Epilepsy
Enrollment 70 participants
Start Date 2024-03
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2023-09-05